## 2. Hepatitis A vaccine and post-exposure prophylaxis

### 2a) Inactivated hepatitis A vaccine versus no intervention

**Author(s):** Wiersma S, Irving G, Ott J, Holden J  
**Date:** 2011-06-29  
**Question:** Should use of inactivated hepatitis A vaccine in family contacts of confirmed cases versus no intervention be used for hepatitis A prevention?  
**Settings:** Trial

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of studies</td>
<td>Design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>1</td>
<td>randomized trial</td>
<td>serious inconsistency</td>
<td>no serious inconsistency</td>
<td>no serious indirectness</td>
</tr>
</tbody>
</table>

1 Sequence generation was unclear, allocation concealment was inadequate, blinding was unclear, and incomplete outcome data was reported.

**Reference**  
2b) Inactivated hepatitis A vaccine versus IG

**Author(s):** Wiersma S, Irving G, Ott J, Holden J  
**Date:** 2011-06-29  
**Question:** Should use of inactivated hepatitis A vaccine in contacts of confirmed cases versus immunoglobulins (IG) be used for post-exposure prevention of hepatitis A?  
**Settings:** Trial

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Other considerations</th>
<th>Risk of bias</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Imprecision</th>
<th>Use of inactivated hepatitis A vaccine in contacts of confirmed cases</th>
<th>Immunoglobulins (IG)</th>
<th>Relative (95% CI)</th>
<th>Absolute</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>hepatitis A (follow-up 4-8 weeks; assessed with: clinical and laboratory criteria)</td>
<td>1 randomized trial</td>
<td>no serious risk of bias</td>
<td>no serious inconsistency</td>
<td>no serious indirectness</td>
<td>no serious imprecision¹</td>
<td>none</td>
<td>25/568 (4.4%)</td>
<td>17/522 (3.3%)</td>
<td>RR 1.35 (0.7 to 2.67)</td>
<td></td>
<td>NOTE² HIGH CRITICAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RR= Relative Risk (95% CI)

¹ Criterion of noninferiority met; no significant differences between IG and inactivated hepatitis A vaccine in clinical or subclinical hepatitis A. Risk of hepatitis in vaccine group never >1.5% than in IG group.

² Absolute vaccine efficacy not assessed.

**Reference**  